PAVmed Inc. (NASDAQ:PAVM – Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $3.95 and traded as low as $2.04. PAVmed shares last traded at $2.05, with a volume of 14,828 shares trading hands.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $56.00.
Get Our Latest Stock Analysis on PAVM
PAVmed Price Performance
The stock has a market capitalization of $16.40 million, a price-to-earnings ratio of -0.13 and a beta of 0.69. The business’s fifty day moving average price is $3.95 and its 200-day moving average price is $5.49. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.19 and a quick ratio of 1.19.
Hedge Funds Weigh In On PAVmed
An institutional investor recently bought a new stake in PAVmed stock. BlackRock Inc. purchased a new stake in shares of PAVmed Inc. (NASDAQ:PAVM – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 17,092 shares of the company’s stock, valued at approximately $102,000. BlackRock Inc. owned about 1.71% of PAVmed as of its most recent filing with the SEC. Hedge funds and other institutional investors own 19.93% of the company’s stock.
About PAVmed
PAVmed Inc is a medical device and diagnostics company focused on developing and commercializing technologies intended to improve the diagnosis and treatment of serious medical conditions. The company operates through subsidiaries and strategic business units that address areas including cancer detection, remote patient monitoring, vascular access and minimally invasive procedures.
One of PAVmed’s primary businesses is its majority-owned subsidiary Lucid Diagnostics, which developed the EsoGuard DNA test and EsoCheck cell-collection device.
Recommended Stories
- Five stocks we like better than PAVmed
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
